These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 8905214)

  • 1. Advanced glycosylated end-products (AGEs) in non-diabetic patients undergoing dialysis.
    Brunkhorst R; Kruse M; Ehlerding G; Mahiout A
    Clin Nephrol; 1996 Oct; 46(4):265-6. PubMed ID: 8905214
    [No Abstract]   [Full Text] [Related]  

  • 2. Peritoneal dialysis for patients with diabetes and end-stage renal disease: sorting out the biases?
    Finkelstein FO; Smith JD
    ASAIO J; 1996; 42(1):1-3. PubMed ID: 8808447
    [No Abstract]   [Full Text] [Related]  

  • 3. Immunohistochemical study of human advanced glycosylation end-products (AGE) in chronic renal failure.
    Yamada K; Miyahara Y; Hamaguchi K; Nakayama M; Nakano H; Nozaki O; Miura Y; Suzuki S; Tuchida H; Mimura N
    Clin Nephrol; 1994 Dec; 42(6):354-61. PubMed ID: 7882598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The meaning of serum levels of advanced glycosylation end products in diabetic nephropathy.
    Shimoike T; Inoguchi T; Umeda F; Nawata H; Kawano K; Ochi H
    Metabolism; 2000 Aug; 49(8):1030-5. PubMed ID: 10954022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Continuous ambulatory peritoneal dialysis: is long-term therapy possible?].
    Olszowska A; Antosiewicz S; Pietrzak B
    Pol Merkur Lekarski; 2000 Dec; 9(54):845-8. PubMed ID: 11255652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advanced glycation end products in end-stage renal disease and their removal.
    Schinzel R; Münch G; Heidland A; Sebekova K
    Nephron; 2001 Apr; 87(4):295-303. PubMed ID: 11287772
    [No Abstract]   [Full Text] [Related]  

  • 7. Enhanced plasma levels of advanced glycation end products (AGE) and pro-inflammatory cytokines in children/adolescents with chronic renal insufficiency and after renal replacement therapy by dialysis and transplantation--are they inter-related?
    Sebeková K; Podracká L; Heidland A; Schinzel R
    Clin Nephrol; 2001 Dec; 56(6):S21-6. PubMed ID: 11770807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kidney transplantation decreases the tissue level of advanced glycosylation end-products.
    Lee WK; Akyol M; Shaw S; Dominiczak MH; Briggs JD
    Nephrol Dial Transplant; 1995; 10(1):103-7. PubMed ID: 7724002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The association of advanced glycation end-products with glutathione status.
    Sahin E; Göçmen AY; Koçak H; Tuncer M; Gümüslü S
    Ann Clin Biochem; 2008 Jul; 45(Pt 4):369-74. PubMed ID: 18583621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased serum levels of advanced glycation end products in NIDDM patients with diabetic complications.
    Ono Y; Aoki S; Ohnishi K; Yasuda T; Kawano K; Tsukada Y
    Diabetes Care; 1998 Jun; 21(6):1027. PubMed ID: 9614627
    [No Abstract]   [Full Text] [Related]  

  • 11. Advanced glycation endproducts (AGEs) as uremic toxins.
    Schwenger V; Zeier M; Henle T; Ritz E
    Nahrung; 2001 Jun; 45(3):172-6. PubMed ID: 11455783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term survival on peritoneal dialysis in end-stage renal disease owing to diabetes.
    Passadakis P; Thodis E; Vargemezis V; Oreopoulos D
    Adv Perit Dial; 2000; 16():59-66. PubMed ID: 11045263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy of the administration of intraperitoneal insulin in diabetic patients undergoing continuous ambulatory peritoneal dialysis].
    Coronel Díaz F; Naranjo Gómez P; Serrano Heranz R; Cruceyra Ventín A; Prats Sánchez D
    Med Clin (Barc); 1984 May; 82(20):881-4. PubMed ID: 6379332
    [No Abstract]   [Full Text] [Related]  

  • 14. [Control of the blood sugar level in patients with diabetic nephropathy undergoing CAPD].
    Numata I; Suzuki M
    Kango Gijutsu; 1987 Feb; 33(3):290-3. PubMed ID: 3646349
    [No Abstract]   [Full Text] [Related]  

  • 15. Low-molecular but not high-molecular advanced glycation end products (AGEs) are removed by high-flux dialysis.
    Gerdemann A; Lemke HD; Nothdurft A; Heidland A; Münch G; Bahner U; Schinzel R
    Clin Nephrol; 2000 Oct; 54(4):276-83. PubMed ID: 11076103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of prostaglandin E1 on peritoneal membrane transport in CAPD-treated diabetic patients.
    Jaroszynski AJ; Ksiazek A
    Perit Dial Int; 2008; 28(5):538-40. PubMed ID: 18708549
    [No Abstract]   [Full Text] [Related]  

  • 17. Clearance of increased serum advanced glycosylation end products in patients with end stage renal disease by hemodialysis.
    Liu NF; Sun ZL; Liu BC
    Acta Pharmacol Sin; 2000 Mar; 21(3):276-80. PubMed ID: 11324431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Continuous peritoneal dialysis of diabetic patients with end-stage renal insufficiency].
    Frandsen NE; Jacobsen IA; Pedersen FB
    Ugeskr Laeger; 1986 Feb; 148(9):513-6. PubMed ID: 3961997
    [No Abstract]   [Full Text] [Related]  

  • 19. Estimate the insulin absorption in diabetic patients on peritoneal dialysis.
    Pantsulaia T; Chokhonelidze I; Lomitashvili T
    Georgian Med News; 2006 Nov; (140):28-30. PubMed ID: 17179582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peritoneal protein losses in diabetic patients starting peritoneal dialysis: is there a relationship with diabetic vascular lesions?
    Coronel F; Cigarrán S; Herrero JA; Delgado J; Ramos F; Gomis A
    Adv Perit Dial; 2009; 25():115-8. PubMed ID: 19886331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.